ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline

Saturday, February 8, 2020

Submitted by

Mark Ferguson

Source

Source Name: Journal of Clinical Oncology

Source URL: https://ascopubs.org/doi/full/10.1200/JCO.19.02748

Author(s)

Bryan J. Schneider, Nofisat Ismaila, Joachim Aerts, Caroline Chiles, Megan E. Daly, Frank C. Detterbeck, Jason W.D. Hearn, Sharyn I. Katz, Natasha B. Leighl, Benjamin Levy, Bryan Meyers, Septimiu Murgu, Larissa Nekhlyudov, Edgardo S. Santos, Navneet Singh, Joan Tashbar, David Yankelevitz, and Nasser Altorki

The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of recommendations is moderate. CT is recommended as the optimal imaging modality. Of interest, PET and circulating biomarkers are not recommended for routine surveillance.